
New ADCs Expand Options for HER2+ and MET+ Lung Cancer
This transcript has been edited for clarity. Hello, this is Mark Kris from Memorial Sloan Kettering. I’m speaking today about new developments in the field of lung adenocarcinomas and squamous carcinomas. We have two new drugs, new targets for this …